Small molecule discovery offers hope for treatment of Angelman syndrome

FHS
July 8, 2024
12:39 pm

Angelman syndrome is a rare genetic disorder caused by mutations in the maternally-inherited UBE3A gene and characterized by poor muscle control, limited speech, epilepsy, and intellectual disabilities.

Sapio Sciences launches new multimodal registration capabilities for its lab informatics platform

Sapio Sciences has enhanced its lab informatics platform.

April 18, 2024

Seaport Therapeutics Launches with $100 Million Oversubscribed Series a Financing Round to Advance Novel Neuropsychiatric Medicines | Psychedelic Invest

BOSTON – Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing

April 10, 2024

New pathway to combat cardiovascular disease identified

Research led by the University of Minnesota Medical School identified a new pathway to combat cardiovascular disease. The study was recently published in Nature Cardiovascular

November 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.